Ian Read adds a new post to his growing roster of post-Pfizer positions — and this one pays well
Ian Read may have to pick up the pace a bit to meet the swelling number of jobs he’s added to his resume since recently retiring from Pfizer after a 41-year run that included 9 years at the top.
Today we learned that Read is taking the chairman’s spot on the board of tech player DXC, a data management outfit that has a big focus on healthcare and the life sciences industry. Read is being well paid for his time and attention. Their SEC filing notes that the ex-Pfizer CEO and chairman will earn an annual retainer of $450,000 in stock, pro-rated to his March 16 start date.
“In DXC, I see the makings of a true global leader in IT services,” Read said in a prepared remark.
Less certain is what the Carlyle Group is paying Read after he joined their team a few weeks ago as a deal scout. Read is also a longtime board member of Kimberly-Clark, where he has been a fixture for the past 13 years.
Private equity has considerable attractions for ex-pharma CEOs, as ex-Sanofi CEO Olivier Brandicourt could attest to. He popped up at JP Morgan last month taking meetings for his new post with Blackstone’s life sciences team as they prep a $4.5 billion fund.